Enzo Biochem (NYSE:ENZ) (NYSE: ENZ) is a biotechnology company specializing in the development, manufacturing and commercialization of proprietary research products, clinical diagnostic products and laboratory services. Founded in 1976 and headquartered in Farmingdale, New York, Enzo leverages its expertise in molecular biology and biochemistry to offer a wide range of reagents, assays and kits for life science research, drug discovery and clinical diagnostics. The company’s technologies include nucleic acid probes, monoclonal antibodies and cell-based assay platforms designed to advance research in areas such as oncology, infectious diseases and personalized medicine.
Through its Clinical Laboratory Services segment, Enzo operates specialty laboratories that provide comprehensive diagnostic testing to hospitals, outpatient facilities and physician practices across the United States. The clinical portfolio covers genetic testing, oncology panels, infectious disease assays and toxicology screening. Enzo’s labs utilize both traditional and molecular diagnostic techniques, including polymerase chain reaction (PCR) and next-generation sequencing (NGS), to deliver timely and accurate results that support patient care and treatment decisions.
In its Research Products and Services segment, Enzo develops and markets a broad array of research reagents and tools for academic, government and pharmaceutical customers worldwide. Products include ELISA kits, nucleic acid labeling systems, fluorescence-based detection reagents and customized antibody production services. The company’s focus on high-quality, reproducible reagents and its integrated logistics and distribution network enable researchers to accelerate experimental workflows from target discovery through preclinical development.
Over its history, Enzo Biochem has expanded its global footprint through strategic partnerships and acquisitions, establishing manufacturing and distribution operations in North America, Europe and Asia. The company maintains regulatory compliances, such as FDA and CE mark approvals, for its clinical products, and holds numerous patents for its proprietary technologies. Under the leadership of President and CEO Gerard J. Sweeney, Enzo continues to invest in innovation and operational excellence to address evolving needs in life sciences research and precision diagnostics.
